Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies.

Drug Category: Array
Conference Category: Array
Lead Author: Nastoupil L, et al.
Published Date: 20/06/2015
Download Link: /wp-content/uploads/2019/03/Triplet%20Phase%20I%20Loretta%20Lugano%202015.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top